Conclusion: The SKP2 gene could be an additional diagnostic and an independent prognostic marker for predicting treatment responses in first-line IM-treated CML patients at an early time point (3 months). This evidence concerns the gene SKP2 and chronic myelogenous leukemia, BCR-ABL1 positive.